Lantern Pharma (NASDAQ:LTRN) posted its earnings results on Monday. The company reported ($0.24) EPS for the quarter, beating analysts’ consensus estimates of ($0.27) by $0.03, MarketWatch Earnings reports.

NASDAQ:LTRN traded down $0.49 during midday trading on Tuesday, hitting $15.49. 500 shares of the company traded hands, compared to its average volume of 197,372. The firm’s fifty day moving average is $17.79 and its 200-day moving average is $17.17. Lantern Pharma has a 12-month low of $10.40 and a 12-month high of $24.84. The company has a debt-to-equity ratio of 0.01, a quick ratio of 27.58 and a current ratio of 27.58.

Lantern Pharma Company Profile

Lantern Pharma Inc, a clinical stage biotechnology company, focuses on the development of precision oncology therapies using artificial intelligence, genomics, and machine learning. Its advanced drug candidate is LP-100, which is in phase II clinical trials to treat metastatic, castration-resistant, prostate cancer.

Recommended Story: Why are trading ranges significant?

Receive News & Ratings for Lantern Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantern Pharma and related companies with MarketBeat.com's FREE daily email newsletter.